

Oregon Drug Use Review Board

Office of Medical Assistance Programs
State of Oregon
February 5, 2002
Meeting Minutes

The meeting was held at the Department of Human Services Building, 500 Summer Street NE, Salem, Room 137ab.

BOARD MEMBERS present: Rick Asai, D.M.D., Gregory Johnson, M.D., Patrick Bowman, R.Ph., Christina Heinrich, Pharm. D., Robert Ingle, M.D., Cliff Singer, M.D. and Dean Haxby, Pharm. D.

BOARD MEMBERS absent: Robert Mendelson, M.D., Raymond Lee, D.O., Sharon Leigh, Pharm. D., Gerald D. Fairbanks, R.Ph and Jim Winde, M.D.

OMAP STAFF and CONTRACTORS present: Thomas Drawbaugh (OMAP), Rose-Ellen Hope (FHSC), Kathy Ketchum (OSU), Kurt Furst (OMAP), Sarah Fryberger (OHPR) and Terah Pernak (OSU).

GUESTS present: Jim Goddard (Shire), Dennis Sagendorf (Purdue Pharma), and Tracy Davies (Eli Lilly).

I. CALL TO ORDER

a. Roll call was taken and introductions were made. The meeting was called to order by Ch. Asai at 1:35 PM. A quorum was not present.

Action: All action items will be reviewed with absent members and brought back for discussion if those members do not concur with the action.

b. The minutes were approved with no corrections. The agenda was approved.

c. Conflicts of Interest were declared.

d. There was no public comment.

II. OLD BUSINESS

a. Anticonvulsant Use Review

The proposed PA criteria were reviewed.

Action: Specific ICD9 ranges were requested for neuropathic pain and bipolar indications.

Action: Add clarification that only covered indications would be approved for treatment.

Action: Board asked that comments be solicited from pain and mental health organizations prior to next meeting.

b. Sedative/Hypnotic Use Criteria

Action: Addition of triazolam, flurazepam, temazepam, estazolam, and quazepam to criteria.

Action: Dr. Singer to work with Dr. Hamer to develop tools and alternatives for practitioners to use during the implementation period.

c. Bronchodilator DUR

Tabled

d. Child Vaccination DUE

Tabled

III. REPORTS

a. OMAP Drug Utilization PMPM Report

The Board reviewed the report.

b. New Drug Report

The Board reviewed the report.

Action: The College will discontinue this regular report as it duplicates reports from FHSC and produce in depth reviews upon request.

c. ProDUR Alert Analysis by Class

The Board reviewed the report.

d. Review of Fluoroquinolones

Action: The Board recommended a DUR Newsletter review article addressing FQ use.

e. ProDUR Report & FHSC Clinical Alerts

The Board reviewed the report.

f. ProDUR Criteria Review

The Board reviewed ProDUR Criteria for the FQ Drugs

Action: Ms. Hope to research severity level of warfarin/ciprofloxacin interaction.

Action: The Board adopted the criteria in the attached grids.

g. RetroDUR Report

The Board reviewed the report. Ms. Hope reported the Council is still recruiting for a pharmacist member.

Action: Board recommended RetroDUR criteria for venlafaxin ER maximum dose be increased to 300mg/day.

h. Education Report

Ms. Ketchum reported the January DUR Board Newsletter on the Carisoprodol PA was pulled because the implementation date was delayed. Issues are planned monthly again starting in February. Regular educational list-serve notices will begin in the next month.

i. HRC Report

Dr. Fryberger reported the progress of the HRC subcommittees evaluating drug classes for effectiveness and safety. The HRC expects to have selected preferred drugs by April and forward that information to OMAP for cost evaluation and implementation by May or June. The next 4 classes to be evaluated were selected at the January HRC meeting and include ACEIs & ARBs, CCBs, 'Triptans and Estrogens.

Mr. Furst solicited the Board's feedback on implementation of an exception process for the PMPDP.

IV. NEW BUSINESS

a. Anti-Ulcer PA Recommendations Letter to OMAP.

b. Notice to "Interested Parties" of the DUR Board.

c. COX2 prior authorization has been indefinitely delayed pending the outcome of the HRC process.

Next meeting is scheduled for May 7, 2002, in DHS 137AB at 1:30-4:30.

The meeting adjourned at approximately 3:15 PM by Dr. Asai.

These minutes are respectfully submitted by Kathy L. Ketchum, OSU College of Pharmacy.